At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
BI 10773 (low) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control
In Brief
A Phase 1 clinical trial evaluating BI 10773 (low), Moxifloxacin, and 2 other interventions for Healthy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedSep 2010
Primary CompletionNov 2010
TodayJul 2026
First PostedSep 6, 2010
Enrollment StartAug 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.8 years ago
Interventions
BI 10773 (low)drug
single oral dose
Moxifloxacindrug
single oral dose
BI 10773 Placebodrug
2 times single dose
BI 10773 (high)drug
single oral dose